Healthquad raises INR 750 million to support thematic healthcare companies in India

IMT News Desk
IMT News Desk
· 3 min read

Delhi-based venture capital firm garners strong investor interest from accomplished healthcare professionals and investors and leading institutions from Europe

Healthquad, healthcare focused venture capital fund has achieved its final close with total commitment of INR750 million for investing in thematic and disruptive healthcare business models in India. The Fund is also the first early stage investment vehicle by the leading healthcare private equity investors, Dr. Amit Varma, Abrar Mir and Charles Antione Janssen.

The Fund targets to invest around INR 4 billion in healthcare companies that have the potential to disrupt the healthcare landscape by dramatically improving the productivity, affordability and accessibility of healthcare through differentiated and innovative solutions.

The Fund’s investment strategy targets five key healthcare sub-sectors including Healthcare Delivery Services, Life-Sciences, Medical Devices & Technology, Healthcare IT and Associated Healthcare Services. It is looking to invest in 8-10 companies. Prior to its final close, the Fund has already made investment in four companies including the recently announced investment in Regency Healthcare.

Fund’s sponsor Dr Amit Varma said:“Healthcare sector has seen emergence of over 500 startups in the last two years and venture capital firms have infused around INR25billion. We are looking to deploy around INR 4 billion, along with co-investors and partner funds in healthcare models that are driven by new age disruptive technology and are changing the way healthcare is delivered and accessed in India.”

Fund’s co-sponsor and his colleague Abrar Mir, added: “Our deployments in healthcare across sub-sectors and geographies provide extensive synergies to help companies scale-up rapidly and that forms the basis of our compelling proposition to healthcare entrepreneurs in India.”

Charles Antione Janssen, Fund’s third co-sponsor added: “Our first four Healthquad investments have confirmed that business model innovations and health tech innovations will open access to quality healthcare for hundreds of millions of neglected Indians. Our final close will allow us to fund more, fast growing, profitable and high impact companies. We look forward to supporting great entrepreneurs for the benefit of patients as well as our LPs.”

The Indian healthcare sector is valued at over INR 7 trillion and is growing at a rate of over 15% p a making it one of the most attractive sectors for investment by the private sector.  An imperative part within all this is the new age models that are unshackling the traditional forms of healthcare delivery and products including digitization of services and product innovation and disintermediation of delivery models. All these are being driven by the need to provide access, affordability and quality.

Healthquad aims to support high quality entrepreneurial talent driving business models that aim to provide thematic and disruptive solution to access, affordability and quality. With the help of its high quality operating team and network, Healthquad provides a unique and strong proposition of mentoring

Companies to build robust business plan and supporting them in their growth strategy by providing access to its vast network of business contacts in the healthcare sector.

 

Read Next

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management
Corporate
January 27, 2026

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management

Company to launch product after the expiry of semaglutide patent in India Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to […]
Article by: IMT News Desk
Lupin receives highest ESG rating from CDP for climate change and water security
Corporate
January 27, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level Lupin has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency […]
Article by: IMT News Desk
AstraZeneca Pharma India receives CDSCO approval for breast cancer drug
Corporate
December 19, 2025

AstraZeneca Pharma India receives CDSCO approval for breast cancer drug

Dato-DXd is a specifically engineered antibody drug conjugate that targets TROP2, a protein frequently overexpressed in breast cancer AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to import, sell, and distribute Datopotamab Deruxtecan (Dato-DXd) in India. The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at […]
Article by: IMT News Desk
Novo Nordisk launches Ozempic in India
Corporate
December 12, 2025

Novo Nordisk launches Ozempic in India

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living […]
Article by: IMT News Desk